TMCnet News
OTC ADVISORS, LLC: Huge Alert On: (OTCBB:NNVC) - (OTCBB:NXWI) - (OTCBB:MPML)Rochester NY, Jun 22, 2010 (M2 PRESSWIRE via COMTEX) -- www.otc-advisors.com names (OTCBB:NNVC)NanoViricides, Inc. (OTCBB:NXWI) Nexaira Wireless, Inc. and (OTCBB:MPML) MPM Technologies, Inc. its "Bulls of the day"! Visit: www.otc-advisors.com for current profiles. To feature your publicly traded company in our alerts email us at [email protected]. To sign up for our free newsletter or to be added to our Quarterly Investment Magazine visit http://www.otc-advisors.com/contact.htm Also, you can receive up to the minute stock alerts via our Twitter/Facbook page. www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296 ------------------------------------------------------------------------------------------------------------------------------------------------------------ Visit: www.otc-advisors.com About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. News Today: WEST HAVEN, Conn., Jun 21, 2010 -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley). Treatment with one of the anti-Dengue nanoviricides(R) led to survival of 50% of the animals for the duration of study in the ADE model. In addition, animals treated with several anti-Dengue nanoviricides survived longer than the control animals treated with vehicle alone. This ADE model of infection is uniformly fatal in 100% of the infected animals within 5 days after infection. Dr. Harris is a leading researcher in the field of dengue viruses. Her group has developed a unique animal model for the most severe and potentially fatal form of Dengue virus infection in humans, Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS). The model emulates the "Antibody-Dependent Enhancement (ADE)" of Dengue virus infection in humans that is believed to lead to DHF/DSS. "We are very excited about these results," said Professor Harris, adding, "This is a very important demonstration of a viable drug candidate leading to significant survival in the ADE model of Dengue virus infection. I believe nanoviricides show great promise in our model and against severe dengue disease." "The first screen has already shown that we are on the right path," said Anil R. Diwan, PhD, President of the Company, adding, "We believe we have at least one potential drug candidate against Dengue now." "We have been able to produce an effective drug candidate against dengue in a very short time," said Eugene Seymour, MD, MPH, Chief Executive Officer of the Company, adding, "This demonstrates the strength of the nanoviricides technology platform." The Company has previously reported significant efficacy of several nanoviricides in two different in vitro (cell culture) tests against dengue virus type 2 conducted by Professor Harris' Lab. Some of these nanoviricides were tested in vivo in the present study. Dengue is receiving significant international attention as it threatens over 40% of the world population, according to WHO. Dengue cases with significant fatality rates have started rising in tropical countries this year already, as demonstrated by reports from India, Sri Lanka, Indonesia, Philippines, Cambodia, and Colombia, among others. Dengue is endemic in Asia, Mexico, the Caribbean, Central America and many countries in South America. Dengue virus infections have occurred in the southern US states, including a current outbreak in Key West, and travel leads to sporadic cases of dengue in the US. Foundations run by Bill Gates and Carlos Slim are now teaming up with Spain to donate a total of $150 million to fight dengue fever, malaria and malnutrition in Mexico and Central America under the 2015 Meso-American Health Initiative (http://blog.taragana.com/health/2010/06/14/bill-gates-carlos-slim-announce-150-million-health-donation-for-mexico-central-america-24172/ ). Dengue virus, a member of the Flaviviridae family of viruses that includes West Nile and Hepatitis C viruses, is transmitted to humans via female Aedes mosquitoes. There are 4 different serotypes of Dengue virus that infect humans. When a person is infected with Dengue virus for the first time, the disease may not be severe, inducing fever, muscle and joint pain, and rash. When the same person is later infected by a different Dengue virus serotype a more severe disease may develop; Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) occurs in a significant portion of this population. This DHF/DSS may be due to ADE caused by antibodies produced during the first infection. According to the WHO, fatality rates of DHF/DSS can exceed 20%. Currently there are no approved vaccines for prevention nor drugs for treatment of Dengue virus infection. About Dr. Eva Harris' Laboratory at the University of California, Berkeley The Harris Laboratory in the Division of Infectious Diseases in the School of Public Health at the University of California, Berkeley (www.Berkeley.edu) has developed a multidisciplinary approach to study the molecular virology, pathogenesis, and epidemiology of dengue, the most prevalent mosquito-borne viral disease in humans. Their work addresses viral and host factors that modulate disease severity. One major research focus has been the development of a mouse model to study viral tropism and pathogenesis, investigate the immune response to dengue virus infection, and evaluate candidate anti-viral therapeutics. Dr. Harris' field work focuses on laboratory-based and epidemiological studies of dengue in endemic Latin American countries, particularly in Nicaragua, where ongoing projects include clinical and biological studies of severe dengue, a pediatric cohort study of dengue and influenza transmission in Managua, and a project on evidence-based, community-derived interventions for prevention of dengue via control of its mosquito vector. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Visit: www.otc-advisors.com About Nexaira Wireless Nexaira's cellular solutions are simple to install, yet provide the advanced management and business class features demanded by the most sophisticated users. Nexaira's wireless devices are ideal for high availability applications acting as the primary router for wireless, DSL, landline or cable networks or can be used to provide complete device and network redundancy in wide area network-failover/fail back applications. For further information on how Nexaira is uniquely positioned to bridge the gap between wireline and wireless services by providing businesses the assurance that their operations will continue during wireline network service interruptions, visit our website at www.nexaira.com Nexaira, Inc. is based in San Diego and is a wholly owned subsidiary of Nexaira Wireless Inc. News Today: SAN DIEGO, Jun 21, 2010 -- Nexaira Wireless Inc. ("Nexaira") (OTCBB: NXWI) is pleased to announce the signing of a Value Added Reseller (VAR) Agreement with Premier Wireless Solutions, a wireless distributor of value-added services such as integration, certification, and cellular data plans for major carriers and MVNOs in the M2M Wireless Market. Premier Wireless Solutions focuses primarily on distributing quality wireless products to system integrators who see the value of incorporating 3G routers into ATM, Kiosk and other stand alone products. Nexaira's Business Class II Router (the "BCII") provides high availability, redundancy, and advanced network management functionality unrivaled in the wireless routing market. "Premier Wireless will clearly be able to assist us in increasing sales and extending our reach to system integrators," said Bob Young, EVP of Business Development for Nexaira. "The BCII's open source environment allows any network management system to be integrated with its open source management tools (OMA DM, FOTA, CLI, XML and others) so systems integrators are not locked into a restrictive, proprietary management system". "We are focused on systems integrators and value added resellers, primarily in the M2M Wireless Market. We selected the Nexaira BCII for its ease of use, its high performance, and its advanced security and redundancy features. Also, since it is based on open source Linux platform, our systems integrators and value added resellers can customize the product to integrate it with their projects," said Tom Gricius, VP of Sales for Premier Wireless Solutions. Choose the freedom of Nexaira. For more information about Nexaira's family of products, please visit http://nexaira.com/i3-interactive-demo/index.html ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- Visit: www.otc-advisors.com About MPM Technologies, Inc. MPM Technologies, Inc. is a holding company with three subsidiaries: Nupower, Inc., which is engaged in the development and commercialization of Skygas(TM); AirPol, Inc., which builds, installs, and services industrial air pollution control systems; and MPM Mining, Inc., an exploration and development company with gold and silver mining properties in Montana. Find more information at www.mpmtech.com. Foton Technologies, LLC, a Florida based company, is involved in the evaluation and development of technologies for production of renewable power, fuels, and chemicals, and - more specifically - the conversion of biomass to syndiesel and to electrical power via gasification. News Today: PARSIPPANY, N.J., Jun 21, 2010 -- MPM Technologies, Inc. (OTCBB:MPML) announced that it has entered into a strategic alliance Agreement with Foton Technologies, LLC to develop projects utilizing Skygas gasification-derived syngas to produce power, chemicals, and liquid fuels via systems and processes designed and supplied by Foton. The Consortium will work together to finalize projects jointly under development by the team and explore new worldwide markets. MPM CEO Michael J. Luciano stated, "The MPM -- Foton cooperation actually started back in early 2008, and we have been working on a number of projects, three of which are close to fruition. This agreement further reinforces our existing relation and greatly enhances our joint strength. Together we will be able to provide the best service and performance to our customers and users in the emerging waste-to-energy field." Foton CEO Don Hendrick noted that the Skygas gasifier was one of a very small number of gasifiers out of the hundreds of thermochemical processes vetted that met Foton's stringent requirements for product gas quality and overall efficiency of operation. Skygas(TM) is a unique electrokinetic process that converts solid and semisolid carbonaceous wastes into a clean-burning synthesis gas that can be utilized to produce power via steam or gas turbines or can be catalytically converted to synthetic chemicals or liquid fuels. Skygas(TM) overcomes the shortcomings generally associated with incineration and thermal and plasma arc gasification methods. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- Visit: www.otc-advisors.com About OTC-ADVISORS.COM OTC-ADVISORS.COM is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTC-ADVISORS. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. For additional information: [email protected], www.otc-advisors.com, www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296 CONTACT: OTC-ADVISORS.COM e-mail: [email protected] WWW: http://www.otc-advisors.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected]. |